Key result
Endomyocardial biopsy with mass spectrometry identifies rare apolipoprotein A-IV amyloidosis missed by standard noninvasive testing.
Why the study?
Rarer forms of cardiac amyloidosis such as apolipoprotein A-IV may not be detected by current noninvasive diagnostic algorithms relying on monoclonal protein assessment and bone scintigraphy.
Case Report (n=2)
Tissue diagnosis with proteomic typing is essential for accurate diagnosis of cardiac amyloidosis when clinical suspicion is high and non-biopsy diagnostic algorithms are discordant, averting false reassurance or inappropriate chemotherapy.
Requires biopsy confirmation when noninvasive testing is discordant in suspected cardiac amyloidosis; leaves open whether algorithms suffice for rare ApoA-IV subtypes.
Cardiac amyloidosis is most commonly caused by transthyretin or immunoglobulin light-chain deposition, and contemporary diagnostic algorithms rely on monoclonal protein assessment and technetium-labeled bone scintigraphy to identify these subtypes. However, rarer forms of amyloid may not be detected by noninvasive testing. We present 2 cases of biopsy-proven apolipoprotein A-IV (ApoA-IV) cardiac amyloidosis illustrating complementary diagnostic pitfalls. The first patient demonstrated classical clinical and multimodality imaging features of cardiac amyloidosis despite negative monoclonal protein studies and pyrophosphate scintigraphy. Endomyocardial biopsy with mass spectrometry confirmed ApoA-IV. The second patient had abnormal serum-free light chains and bone marrow plasma cell involvement suggestive of light-chain amyloidosis, yet cardiac biopsy revealed ApoA-IV, preventing inappropriate chemotherapy. These cases highlight limitations of current nonbiopsy algorithms and emphasize that tissue diagnosis with proteomic typing remains essential when clinical suspicion is high or findings are discordant.
No takes yet. Share an insight, caveat, or question.
Helmy et al. (2026) conducted a case report in Apolipoprotein A-IV Cardiac Amyloidosis (n=2). Endomyocardial biopsy with mass spectrometry vs. Contemporary noninvasive diagnostic algorithms (pyrophosphate scintigraphy and monoclonal protein testing) was evaluated. Endomyocardial biopsy with mass spectrometry definitively diagnosed rare apolipoprotein A-IV cardiac amyloidosis in two patients where standard noninvasive algorithms were falsely reassuring or confounded by coexisting monoclonal gammopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: